错配修复基因2与卵巢癌紫杉醇化疗耐药相关性研究  

Mismatch repair gene hMSH2 and paclitaxel resistance of ovarian cancer

作　　者：李健[1] 李红霞[1] 

机构地区：[1]首都医科大学附属北京世纪坛医院妇产科,北京100038

出　　处：《中华肿瘤防治杂志》2015年第11期836-839,共4页Chinese Journal of Cancer Prevention and Treatment

基　　金：国家"十一五"863计划(2006AA02A245)

摘　　要：目的检测人类错配修复基因2(human mismatch repair gene2,hMSH2)在卵巢癌紫杉醇耐药细胞株及卵巢癌组织中蛋白表达的变化,探讨其与卵巢癌紫杉醇化疗耐药的相关性。方法选用卵巢癌紫杉醇耐药细胞株SKOV3/TAX及敏感细胞株SKOV3,选取北京世纪坛医院2010-01-01-2014-06-30卵巢癌患者石蜡标本58例,其中紫杉醇化疗后复发行二次手术的患者标本19例(化疗组),术前未化疗患者39例(未化疗组)。采用免疫组化二步法,检测卵巢癌细胞及组织中hMSH2蛋白表达。结果耐药细胞株SKOV3/TAX中hMSH2蛋白表达强度为50 214.64±27 218.39,明显高于敏感细胞株SKOV3的11 791.79±7 385.98,P=0.016;卵巢癌组织中化疗组hMSH2蛋白表达累积光密度值为74 322.52±27 162.82,较未化疗组的57 244.96±24 332.86明显增加,P=0.019;化疗组及未化疗组两组患者在病理分级(P=0.366)、病理类型(P=0.768)和手术病理分期(P=0.533)差异均无统计学意义;全部卵巢癌组织中hMSH2蛋白表达在病理分级(P=0.161)、病理类型(P=0.649)和手术病理分期(P=0.519)中的分布差异均无统计学意义。结论错配修复基因hMSH2在卵巢癌紫杉醇耐药细胞株及组织中表达上调可能与紫杉醇耐药机制有关。OBJECTIVE To investigate the protein expression of human mismatch repair gene2（hMSH2）in Ovarian cancer cell line and tissues after taxol-chemotherapy,and the association with taxol resistant in ovarian cancer and the clinical significance.METHODS Ovarian cancer cell line SKOV3 and paclitaxel resistant cancer cell line SKOV3/TAX were used.Fifty-eight cases of ovarian cancer tissues were selected,in which 19 cases had received taxol-based chemotherapy before operation（group 1）,and 39 cases hadn＇t received chemotherapy（group 2）.The expression of hMSH2 protein in tissues and cancer cell lines were detected by two-step immunohistochemical method.RESULTS The expression intensity of hMSH2 protein in SKOV3/TAX cell line was much higher than that in the SKOV3 cell line（50 214.64±27 218.39 vs 11 791.79±7 385.98,P=0.016）.The expression intensity of hMSH2 protein in group1 was higher than that in group2（74 322.52±27 162.82 vs 57 244.96±24 332.86,P=0.019）.No significant difference of the distribution was seen between two groups of patients in histological grade,pathological type,and clinical-pathological stage（P values were0.366,0.768 and 0.533respectively）.No significant difference of hMSH2 protein expression was seen in histological grade,pathological type,and clinical-pathological stage（Pvalues were 0.161,0.649 and 0.519respectively）.CONCLUSION The up-regulation of mismatch repair gene hMSH2 may be related to the paclitaxel resistance mechanism in ovarian cancer.

关 键 词：人类错配修复基因2 卵巢癌 紫杉醇耐药 免疫组织化学 

分 类 号：R737.31[医药卫生—肿瘤]